<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35420565</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-712X</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>3</Issue><PubDate><MedlineDate>2022 May-Jun 01</MedlineDate></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants-A Scoping Review.</ArticleTitle><Pagination><StartPage>284</StartPage><EndPage>292</EndPage><MedlinePgn>284-292</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0000000000001543</ELocationID><Abstract><AbstractText Label="PURPOSE/BACKGROUND" NlmCategory="OBJECTIVE">Studies for repurposed drugs in severe acute respiratory syndrome coronavirus type 2-infected and coronavirus disease 2019 (COVID-19) patients are ongoing. According to preclinical research, antidepressants (ADs) might be useful in the treatment of COVID-19.</AbstractText><AbstractText Label="METHODS/PROCEDURES" NlmCategory="METHODS">We conducted a scoping review including clinical studies on AD effects on SARS-CoV-2 infection and COVID-19.</AbstractText><AbstractText Label="FINDING/RESULTS" NlmCategory="UNASSIGNED">As of January 2, 2022, we found 14 clinical studies, which could be included into this review. Among them, there were 2 randomized, placebo-controlled studies and 2 prospective parallel-group studies about the efficacy/effectiveness and tolerability of fluvoxamine. The remaining studies were mainly retrospective studies considering COVID-19 hospital populations predominantly exposed to fluoxetine (N = 3), other selective serotonin reuptake inhibitors (SSRI), selective norepinephrine reuptake inhibitors (SNRI), and trazodone. The vast majority were hospital studies and assessed COVID-19 severity (morbidity) and mortality as primary endpoints. The only outpatient study (fluvoxamine) investigated the COVID-19-related hospitalization rate, and 1 psychiatric hospital study (SSRI, SNRI, trazodone) focused on the SARS-CoV-2 infection rate.</AbstractText><AbstractText Label="IMPLICATIONS/CONCLUSIONS" NlmCategory="CONCLUSIONS">At present, the best evidence of an "anti-COVID-19" potential of ADs exists for fluvoxamine and, to a lesser extent, for fluoxetine. Preliminary evidence had found that patients exposed to SSRI or SNRI substance classes might have a reduced mortality risk and that trazodone might reduce SARS-CoV-2 infection rates. Three studies found no relevant influence of ADs on COVID-19 morbidity and mortality, and 1 study described increased mortality. The latter study, however, did not differentiate between psychotropic medication and ADs. Tricyclics and monoamine oxidase inhibitors are still absolute "dark zones" in COVID-19 research. Further controlled studies testing the effectiveness/efficacy and tolerability/safety (as well as the treatment timing and duration) of different AD substance classes in COVID-19 and post/long-COVID patients of various populations are warranted.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonnet</LastName><ForeName>Udo</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Juckel</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ruhr University Bochum, LWL University Hospital, Bochum, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000068760">Serotonin and Noradrenaline Reuptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>01K63SUP8D</RegistryNumber><NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O4L1XPO44W</RegistryNumber><NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>YBK48BXK30</RegistryNumber><NameOfSubstance UI="D014196">Trazodone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005473" MajorTopicYN="N">Fluoxetine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016666" MajorTopicYN="N">Fluvoxamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068760" MajorTopicYN="Y">Serotonin and Noradrenaline Reuptake Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014196" MajorTopicYN="Y">Trazodone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>12</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35420565</ArticleId><ArticleId IdType="pmc">PMC9042214</ArticleId><ArticleId IdType="doi">10.1097/JCP.0000000000001543</ArticleId><ArticleId IdType="pii">00004714-202205000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barcella CA Polcwiartek C Mohr GH, et al. . Severe mental illness is associated with increased mortality and severe course of COVID-19. Acta Psychiatr Scand. 2021;144:82&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250986</ArticleId><ArticleId IdType="pubmed">33894064</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S Fernandez-Egea E Jones PB, et al. . Longer-term mortality following SARS-CoV-2 infection in people with severe mental illness: retrospective case-matched study. BJPsych Open. 2021;7:e201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8564024</ArticleId><ArticleId IdType="pubmed">34745650</ArticleId></ArticleIdList></Reference><Reference><Citation>Toubasi AA AbuAnzeh RB Tawileh HBA, et al. . A meta-analysis: the mortality and severity of COVID-19 among patients with mental disorders. Psychiatry Res. 2021;299:113856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7927594</ArticleId><ArticleId IdType="pubmed">33740483</ArticleId></ArticleIdList></Reference><Reference><Citation>Vai B Mazza MG Delli Colli C, et al. . Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021;8:797&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285121</ArticleId><ArticleId IdType="pubmed">34274033</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N S&#xe1;nchez-Rico M Herrera-Morueco JJ, et al. . Comorbid medical conditions are a key factor to understand the relationship between psychiatric disorders and COVID-19-related mortality: results from 49,089 COVID-19 inpatients. Mol Psychiatry. 2021;1&#x2013;3. doi: 10.1038/s41380-021-01393-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8622106</ArticleId><ArticleId IdType="pubmed">34837060</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Rico M, Limosin F, Hoertel N. Is a diagnosis of schizophrenia spectrum disorder associated with increased mortality in patients with COVID-19? Am J Psychiatry. 2022;179:71&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">34974753</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman H, Pross S, Klein TW. Addictive drugs and their relationship with infectious diseases. FEMS Immunol Med Microbiol. 2006;47:330&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">16872369</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hler CA Freitas TH Stubbs B, et al. . Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol. 2018;55:4195&#x2013;4206. doi:10.1007/s12035-017-0632-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0632-1</ArticleId><ArticleId IdType="pubmed">28612257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N S&#xe1;nchez-Rico M Vernet R, et al. . Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021;26:5199&#x2013;5212.</Citation><ArticleIdList><ArticleId IdType="pubmed">33536545</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez-Quevedo C Iglesias-Gonz&#xe1;lez M Giralt-L&#xf3;pez M, et al. . Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID-19 Spanish inpatients. Acta Psychiatr Scand. 2021;143:526&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250711</ArticleId><ArticleId IdType="pubmed">33792912</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters MD Godfrey CM Khalil H, et al. . Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13:141&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">26134548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenze EJ Mattar C Zorumski CF, et al. . Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324:2292&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662481</ArticleId><ArticleId IdType="pubmed">33180097</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G Dos Santos Moreira-Silva EA Silva DCM, et al. . Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42&#x2013;e51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8550952</ArticleId><ArticleId IdType="pubmed">34717820</ArticleId></ArticleIdList></Reference><Reference><Citation>Calusic M Marcec R Luksa L, et al. . Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls. Br J Clin Pharmacol. 2021. doi: 10.1111/bcp.15126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653355</ArticleId><ArticleId IdType="pubmed">34719789</ArticleId></ArticleIdList></Reference><Reference><Citation>Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open forum. Infect Dis. 2021;8:ofab050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7888564</ArticleId><ArticleId IdType="pubmed">33623808</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskotsky T Maric I Tang A, et al. . Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open. 2021;4:e2133090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8593759</ArticleId><ArticleId IdType="pubmed">34779847</ArticleId></ArticleIdList></Reference><Reference><Citation>Clelland CL Ramiah K Steinberg L, et al. . Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open. 2021;8:e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8649363</ArticleId><ArticleId IdType="pubmed">34859759</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe9;meth ZK Sz&#xfb;cs A Vitrai J, et al. . Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: a retrospective case-control study. Ideggyogy Sz. 2021;74:389&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">34856085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N S&#xe1;nchez-Rico M Gulbins E, et al. . Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study. Clin Pharmacol Ther. 2021;110:1498&#x2013;1511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8239599</ArticleId><ArticleId IdType="pubmed">34050932</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet U Claus B Schaefer M, et al. . Impact of psychiatric and related somatic medications on the duration and severity of COVID-19: a retrospective explorative multi-center study from the German metropolitan Ruhr-area. Pharmacopsychiatry. 2022;55:30&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">34530483</ArticleId></ArticleIdList></Reference><Reference><Citation>Fei L Santarelli G D'Anna G, et al. . Can SSRI/SNRI antidepressants decrease the 'cytokine storm' in the course of COVID-19 pneumonia? Panminerva Med. 2021. doi: 10.23736/S0031-0808.21.04436-0.</Citation><ArticleIdList><ArticleId IdType="pubmed">34240839</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproule BA Naranjo CA Brenmer KE, et al. . Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997;33:454&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">9435993</ArticleId></ArticleIdList></Reference><Reference><Citation>Hori H Yoshimura R Ueda N, et al. . A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. World J Biol Psychiatry. 2009;10(Pt 2):620&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">18609433</ArticleId></ArticleIdList></Reference><Reference><Citation>Omori IM Watanabe N Nakagawa A, et al. . Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2010;17:CD006114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171125</ArticleId><ArticleId IdType="pubmed">20238342</ArticleId></ArticleIdList></Reference><Reference><Citation>Facente SN Reiersen AM Lenze EJ, et al. . Fluvoxamine for the early treatment of SARS-CoV-2 infection: a review of current evidence. Drugs. 2021;81:2081&#x2013;2089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8633915</ArticleId><ArticleId IdType="pubmed">34851510</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DA Seki SM Fern&#xe1;ndez-Casta&#xf1;eda A, et al. . Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11:eaau5266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6936250</ArticleId><ArticleId IdType="pubmed">30728287</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpinteiro A Edwards MJ Hoffmann M, et al. . Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020;1:100142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598530</ArticleId><ArticleId IdType="pubmed">33163980</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloer S Brunotte L Goretzko J, et al. . Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg Microbes Infect. 2020;9:2245&#x2013;2255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7594754</ArticleId><ArticleId IdType="pubmed">32975484</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunotte L Zheng S Mecate-Zambrano A, et al. . Combination therapy with fluoxetine and the nucleoside analog GS-441524 exerts synergistic antiviral effects against different SARS-CoV-2 variants in vitro. Pharmaceutics. 2021;13:1400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8466181</ArticleId><ArticleId IdType="pubmed">34575474</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimniak M Kirschner L Hilpert H, et al. . The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2 in human lung tissue. Sci Rep. 2021;11:5890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7961020</ArticleId><ArticleId IdType="pubmed">33723270</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci. 2022;272:161&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412866</ArticleId><ArticleId IdType="pubmed">34476589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N S&#xe1;nchez-Rico M Cougoule C, et al. . Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. Mol Psychiatry. 2021;26:7098&#x2013;7099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8359627</ArticleId><ArticleId IdType="pubmed">34385600</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpinteiro A Gripp B Hoffmann M, et al. . Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J Biol Chem. 2021;296:100701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8062550</ArticleId><ArticleId IdType="pubmed">33895135</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J Tripal P Reichel M, et al. . Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26:9&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">20502000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase/ceramide system in COVID-19. Mol Psychiatry. 2021;1&#x2013;8. doi: 10.1038/s41380-021-01309-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8359627</ArticleId><ArticleId IdType="pubmed">34385600</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N. Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19? JAMA Netw Open. 2021;4:e2136510.</Citation><ArticleIdList><ArticleId IdType="pubmed">34779851</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Corre P, Loas G. Repurposing functional inhibitors of acid sphingomyelinase (FIASMAs): an opportunity against SARS-CoV-2 infection? J Clin Pharm Ther. 2021;46:1213&#x2013;1219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014536</ArticleId><ArticleId IdType="pubmed">33645763</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornhuber J Muehlbacher M Trapp S, et al. . Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6:e23852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166082</ArticleId><ArticleId IdType="pubmed">21909365</ArticleId></ArticleIdList></Reference><Reference><Citation>Khodadoust MM. Inferring a causal relationship between ceramide levels and COVID-19 respiratory distress. Sci Rep. 2021;11:20866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531370</ArticleId><ArticleId IdType="pubmed">34675292</ArticleId></ArticleIdList></Reference><Reference><Citation>Torretta E Garziano M Poliseno M, et al. . Severity of COVID-19 patients predicted by serum sphingolipids signature. Int J Mol Sci. 2021;22:10198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8508132</ArticleId><ArticleId IdType="pubmed">34638539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar&#xed;n-Corral J Rodr&#xed;guez-Morat&#xf3; J Gomez-Gomez A, et al. . Metabolic signatures associated with severity in hospitalized COVID-19 patients. Int J Mol Sci. 2021;22:4794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8124482</ArticleId><ArticleId IdType="pubmed">33946479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lionetto L Ulivieri M Capi M, et al. . Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: an observational cohort study. Biochim Biophys Acta Mol Basis Dis. 2021;1867:166042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834629</ArticleId><ArticleId IdType="pubmed">33338598</ArticleId></ArticleIdList></Reference><Reference><Citation>Shader RI. COVID-19, interferons, and depression: a commentary. Psychiatry Res. 2020;291:113198.</Citation><ArticleIdList><ArticleId IdType="pubmed">32535509</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet U Bingmann D Wiltfang J, et al. . Modulatory effects of neuropsychopharmaca on intracellular pH of hippocampal neurones in vitro. Br J Pharmacol. 2010;159:474&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825368</ArticleId><ArticleId IdType="pubmed">20015293</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet U. The sour side of vitamin C might mediate neuroprotective, anticonvulsive and antidepressant-like effects. Med Hypotheses. 2019;131:109320.</Citation><ArticleIdList><ArticleId IdType="pubmed">31443769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ondicova K Tillinger A Pecenak J, et al. . The vagus nerve role in antidepressants action: efferent vagal pathways participate in peripheral anti-inflammatory effect of fluoxetine. Neurochem Int. 2019;125:47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30738079</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>